Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc.verified

CYCN

Price:

$3.2

Market Cap:

$8.67M

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic neph...[Read more]

Industry

Biotechnology

IPO Date

2019-03-18

Stock Exchange

NASDAQ

Ticker

CYCN

The PE Ratio as of December 2024 (TTM) for Cyclerion Therapeutics, Inc. (CYCN) is -1.54

According to Cyclerion Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.54. This represents a change of 5.87% compared to the average of -1.45 of the last 4 quarters.

Cyclerion Therapeutics, Inc. (CYCN) Historical PE Ratio (quarterly & annually)

How has CYCN PE Ratio performed in the past?

The mean historical PE Ratio of Cyclerion Therapeutics, Inc. over the last ten years is -2.03. The current -1.54 PE Ratio has changed 7.50% with respect to the historical average. Over the past ten years (40 quarters), CYCN's PE Ratio was at its highest in in the September 2023 quarter at 0.28. The PE Ratio was at its lowest in in the December 2018 quarter at -55.22.

Quarterly (TTM)
Annual

Average

-2.03

Median

-1.29

Minimum

-5.39

Maximum

-0.37

Cyclerion Therapeutics, Inc. (CYCN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cyclerion Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 107.97%

Maximum Annual PE Ratio = -0.37

Minimum Annual Increase = -79.21%

Minimum Annual PE Ratio = -5.39

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.37-42.76%
2022-0.65-50.04%
2021-1.301.80%
2020-1.28107.97%
2019-0.62-79.21%
2018-2.96-18.51%
2017-3.63-32.57%

Cyclerion Therapeutics, Inc. (CYCN) Average PE Ratio

How has CYCN PE Ratio performed in the past?

The current PE Ratio of Cyclerion Therapeutics, Inc. (CYCN) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

-0.78

5-year avg

-0.84

10-year avg

-2.03

Cyclerion Therapeutics, Inc. (CYCN) PE Ratio vs. Peers

How is CYCN’s PE Ratio compared to its peers?

Cyclerion Therapeutics, Inc.’s PE Ratio is less than Kronos Bio, Inc. (-0.67), greater than Larimar Therapeutics, Inc. (-3.90), less than Addex Therapeutics Ltd (1.05), less than Achilles Therapeutics plc (-0.59), less than Lipella Pharmaceuticals Inc. (-0.00), less than Senti Biosciences, Inc. (-0.26), greater than Fennec Pharmaceuticals Inc. (-140.94), less than Monopar Therapeutics Inc. (-0.65), less than Applied Molecular Transport Inc. (-0.43), greater than Cardio Diagnostics Holdings, Inc. (-3.05), greater than Sigilon Therapeutics, Inc. (-16.76), less than Sonnet BioTherapeutics Holdings, Inc. (-0.18), less than ZyVersa Therapeutics, Inc. (-0.00), greater than X4 Pharmaceuticals, Inc. (-6.92), greater than Axcella Health Inc. (-3.07), less than Magenta Therapeutics, Inc. (-0.15), greater than Kezar Life Sciences, Inc. (-4.91), less than ContraFect Corporation (-0.00), greater than ZIVO Bioscience, Inc. (-5.50), greater than Theseus Pharmaceuticals, Inc. (-6.29), greater than Erasca, Inc. (-4.40), less than Forte Biosciences, Inc. (-1.03),

Build a custom stock screener for Cyclerion Therapeutics, Inc. (CYCN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cyclerion Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cyclerion Therapeutics, Inc. (CYCN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cyclerion Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Cyclerion Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Cyclerion Therapeutics, Inc. (CYCN)?

What is the highest PE Ratio for Cyclerion Therapeutics, Inc. (CYCN)?

What is the 3-year average PE Ratio for Cyclerion Therapeutics, Inc. (CYCN)?

What is the 5-year average PE Ratio for Cyclerion Therapeutics, Inc. (CYCN)?

How does the current PE Ratio for Cyclerion Therapeutics, Inc. (CYCN) compare to its historical average?